Please assess the completion status of the following clinical trial:

Trial Title: The PertADO Geneva Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~The volunteer must satisfy the following criteria to be eligible for the study:~1. Has provided written informed consent before enrollment;~2. Male or female, ages 11-15 years (inclusive) at the time of enrollment;~3. With documented history of acellular pertussis immunization (5 doses);~4. Free of clinically significant health problems, as determined by pertinent medical history and clinical examination at study screening;~5. Non-pregnant, non-lactating female :~   * for female subjects who had menarche, this implies a negative urinary pregnancy test at enrolment;~  * If sexually active, female subjects must be willing to use reliable birth control measures for 1 month after vaccination;~6. Able to attend all scheduled visits and to understand and comply with the study procedures; Exclusion criteria~The volunteer may not enter the study if any of the following apply:~1. Prior dTpa immunization within the last 5 years or prior dT immunization within the last 2 years, or any other investigational vaccine likely to impact on interpretation of the trial data, as judged by the Principal Investigator;~2. Suspected or confirmed pertussis infection within the last 10 years or documented pertussis infection in a household member within the last 10 years;~3. History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions;~4. Known hypersensitivity or allergy to diphtheria, tetanus, or pertussis vaccine (including excipients);~5. Receipt of investigational product up to 30 days prior to enrollment or ongoing participation in another interventional clinical trial;~6. Receipt of licensed vaccines within 30 days of planned study immunization or ongoing participation in another clinical interventional trial;~7. Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the Investigator based on medical history, physical exam;~8. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, asplenia, cytotoxic therapy in the previous 5 years, and/or diabetes;~9. Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding febrile seizures as a child;~10. Has a known history of Guillain-Barré Syndrome;~11. Has an active malignancy or recent (\<10 years) history of metastatic or hematologic malignancy;~12. Suspected or known alcohol and/or illicit drug abuse within the past 5 years;~13. Pregnant or lactating female, or female who intends to become pregnant during the study period;~14. Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period;~15. Receipt of chronic (\>14 days) immunosuppressants or other immune modifying drugs within 6 months of study entry:~    * For corticosteroids, this will mean prednisone or equivalent ≥0.5 mg/kg/day,~   * Intranasal and topical steroids are allowed;~16. Any other significant finding that, in the opinion of the investigator, would increase the risk of the individual's having an adverse outcome by participating in this study.~Temporary exclusion criteria at the time of randomization~The following criteria constitute contraindications to administration of vaccine at that point in time; if any one of these occurs at the time scheduled for randomization, the subject may be randomized at a later date without the need for re-screening, at the discretion of the Investigator, or withdrawn at the discretion of the Investigator:~* Acute disease at the time of randomization. (Acute disease in the context of this trial is defined as the presence of a moderate or severe illness with or without fever.) The vaccine/placebo can be administered to persons with a minor illness such as mild upper respiratory tract infection with or without low-grade febrile illness, i.e. temperature of ≤37.5°C;~* Body temperature ≥38°C within 3 days of the intended vaccination;~* Any other significant finding that, in the opinion of the investigator, would temporarily increase the risk of the individual's having an adverse outcome by participating in this study.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: Pertagen® aP + Td-pur® (Type: EXPERIMENTAL): BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
- Arm 2: Boostrix® dTpa (Type: ACTIVE_COMPARATOR): Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete